Phase 2a Trial to Test Microdoses of the Psychedelic Psilocybin in 10 Patients
KGK Science, a wholly owned subsidiary of Wellbeing Digital Sciences, has entered into an agreement with Nova Mentis Life Science to conduct a Phase 2a clinical trial testing the efficacy of psilocybin as a potential treatment for fragile X syndrome. The open-label trial will be the…